Synfacts 2020; 16(08): 0877
DOI: 10.1055/s-0040-1707096
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag Stuttgart · New York

Synthesis of Sacubitril

Philip Kocienski
Kleinbeck F. * et al. Novartis Pharma AG, Basel, Switzerland
Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696.

J. Org. Chem. 2020;
85: 6844-6853
Further Information

Publication History

Publication Date:
21 July 2020 (online)



Sacubitril is a nephrilysin inhibitor used in combination with the angiotensin II inhibitor valsartan. The combination drug (LCZ696), marketed under the brand name Entresto®, was approved by the FDA in 2015 for the treatment of heart failure. A noteworthy step in the synthesis of sacubitril depicted features a flow reactor to perform the Ivanov reaction (Synthesis 1975, 83) by which the carboxylic acids B and D were condensed to give γ-ketoacid derivative G in 79% yield on a 15.1 mol scale.



The (R,R)-Ph-BPE-derived rhodium complex in methanol at 30 °C and a hydrogen pressure of 10 bar provided the best performance among the catalyst systems screened for the asymmetric hydrogenation of A. Complete conversion into B was observed in concentrations as high as 1.3 g/mL and catalyst loadings as low as S/C 74,000:1, providing the product in high purity and excellent enantioselectivity (er = 99.7:0.3).